- Conditions
- Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Adenocarcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Soft Tissue Sarcoma
- Interventions
- MM-310
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 3,658
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
- Conditions
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Cisplatin, Docetaxel, Laboratory Biomarker Analysis, Nintedanib
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer, Non Small Cell Lung Carcinoma
- Interventions
- Pemetrexed, Matuzumab
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 42
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 36 more
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Prostate Cancer
- Interventions
- imexon, docetaxel
- Drug
- Lead sponsor
- AmpliMed Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
- Interventions
- Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy
- Drug · Procedure
- Lead sponsor
- Persephone Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 10
- States / cities
- Orange, California • San Diego, California • Miami, Florida + 6 more
- Conditions
- KRAS p, G12c Mutated /Advanced Metastatic NSCLC
- Interventions
- AMG 510, Docetaxel
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 54
- States / cities
- Anaheim, California • Duarte, California • Long Beach, California + 46 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- AZD9291
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 9
- States / cities
- La Jolla, California • Orange, California • New Haven, Connecticut + 6 more
- Conditions
- Melanoma, Gastrointestinal Cancer, Metastatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer
- Interventions
- Anti-CD19 CAR PBL
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 7,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- enzastaurin, pemetrexed, carboplatin, bevacizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 12
- States / cities
- Bentonville, Arkansas • Chicago, Illinois • Galesburg, Illinois + 9 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
- Interventions
- Nintedanib
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
- Interventions
- KFA115, pembrolizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Lung Cancer
- Interventions
- docetaxel, gemcitabine hydrochloride, irinotecan hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • St Louis, Missouri • Las Vegas, Nevada + 4 more
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Solid Tumor
- Interventions
- YH42946
- Drug
- Lead sponsor
- Yuhan Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Lung Cancer
- Interventions
- Topotecan, Docetaxel
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma
- Interventions
- GEN-009 Adjuvanted Vaccine, Nivolumab, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- La Jolla, California • Santa Monica, California • Aurora, Colorado + 8 more
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Discussion, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Adenocarcinoma
- Interventions
- Not listed
- Lead sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Ramucirumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more
- Conditions
- Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- docetaxel, bortezomib, laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- a novel mobile phone-based intervention for automated electronic PRO collection
- Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Gilteritinib, Magnetic Resonance Imaging, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
- Interventions
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
- Drug
- Lead sponsor
- Neonc Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- nicotine, Usual Care
- Drug · Behavioral
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 19 Years to 120 Years
- Enrollment
- 434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1990
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania